Gaudium IVF Q1 FY27: Revenue up, margins down as expansion spend ramps

Gaudium IVF and Women Health Limited reported a steady start to FY27 in revenue terms, but a sharp dip in profitability as it front-loaded expansion and brand-building costs. For Q1 FY27, consolidated revenue from operations rose 9.13% year-on-year to INR 19.38 crore (from INR 17.76 crore). Reported consolidated EBITDA fell to INR 2.42 crore (from INR 5.15 crore) and PAT from continuing operations declined to INR 1.78 crore (from INR 3.08 crore).

Management positioned the quarter as a deliberate investment phase tied to a larger rollout plan. The company highlighted pre-operationalisation costs for new hubs, incremental clinical hiring, and expenses linked to integrating AI-led embryology tools (SiD and ERICA). In the concall, management also pointed to a one-time, heavy pan-India marketing push to promote these AI tools as a key contributor to the margin compression.

What changed in Q1: profitability was traded for readiness

The investor presentation shows consolidated EBITDA margin declined to 12.51% in Q1 FY27 from 29.02% in Q1 FY26. PAT margin fell to 9.17% from 17.33%. While the reported performance looks weak on margins, management emphasized adjusted profitability. The company disclosed an adjusted EBITDA of INR 5.33 crore for Q1 FY27, implying a 27.49% margin, after excluding expansion-related and other stated one-offs.

The core business remains IVF-led. Gaudium disclosed a services revenue split with IVF treatment contributing 66.24%, pharmacy 29.41% and hospital services 4.35%. Management acknowledged that pharmacy and hospital services structurally carry lower margins than core IVF, but described them as strategically important for end-to-end patient support and higher wallet share per patient.

The company also reiterated seasonality in IVF demand. In the Q&A, management stated that Q1 is typically softer due to summer heat and patient perceptions, and Q3 tends to be weaker due to festivals, with Q2 and Q4 historically making up for the slow quarters.

Expansion and the Signature Lab approach

Gaudium’s growth pitch is anchored in a hub-and-spoke rollout, supported by standardized processes and technology integration. The presentation states the network comprises 8 hubs and 28 spokes with presence across 9 Indian states.

A key milestone discussed in the concall was the commissioning of a new hub in South Extension, New Delhi. Management said the centre became operational on 16 July 2026 and houses the Gaudium Signature Lab, described as the company’s proprietary laboratory framework that combines AI-powered embryology with standardized clinical protocols and quality standards built over a long operating history.

The rollout cadence is aggressive. The investor presentation outlines a phased plan: 10 new hubs in FY27, 8 new centers in FY28, and 1 new center in FY29. On the earnings call, management indicated Gurgaon is expected to become operational around 10 days from the call date and Nagpur around 25 days from the call date.

The CFO also quantified the capital intensity of a typical hub. According to the concall, average capex per centre is around INR 2.5 crore, split into roughly INR 1 crore of construction cost and INR 1.5 crore for lab machinery. For FY27, the CFO reiterated capex guidance of approximately INR 25 crore for 10 new hubs, funded primarily through IPO proceeds and internal accruals.

AI-led embryology and clinical outcome disclosures

Technology is central to Gaudium’s current positioning. The company highlighted SiD and ERICA as AI tools integrated into embryology workflows, in partnership with IVF 2.0. In the concall, management said the tools were introduced from 1 April 2026 and are being steadily integrated across centres.

The company disclosed clinical performance metrics prominently. It reported a first attempt success rate of 62% and a cumulative pregnancy rate of 85%. Management also stated that early results indicate approximately an 8% improvement in first attempt outcomes in patients where SiD and ERICA have been used. The presentation notes early results show an 8% to 9% increase with these tools.

Operationally, the company framed these tools as a way to reduce subjectivity and standardize outcomes across centres. SiD is described as AI-powered sperm selection for ICSI, while ERICA is positioned as AI-based embryo assessment and classification based on implantation potential.

Beyond IVF: a new women health hospital project

A notable new announcement in the concall was the board’s approval of a Gaudium Women Hospital project in Lucknow. The CFO stated an estimated project cost of up to INR 15 crore, to be incurred progressively through setup and commissioning, with commercialization expected in FY28 to FY29.

Management linked this to the company’s longer-term intent to expand beyond IVF into broader women health, while still calling IVF the core of the planned Lucknow facility. The CFO clarified the Lucknow hospital project will not be funded from IPO proceeds earmarked for the 19 new IVF hubs, and will be funded mainly through internal accruals.

Balance sheet posture and financial discipline

Despite the margin compression in Q1, management emphasized liquidity and leverage discipline. The CFO said the company remains debt-light post IPO. Cash and bank balances as of 30 June were stated at INR 8.12 crore against borrowings of INR 6.74 crore, and consolidated debt-to-equity was stated at approximately 0.04 times.

This matters because the company is simultaneously committing to a multi-centre capex program and stepping into a hospital project with a longer commercialization timeline.

What management guided for FY27

Management provided explicit directional guidance on the call. In response to an investor question, management said it is confident of achieving around 30% year-on-year growth for FY27. Management also indicated that adjusted EBITDA margins are expected to return to levels similar to FY26 by the end of the year, implying that Q1 profitability was impacted by costs that are not expected to repeat at the same intensity.

The next few quarters will be important in validating this narrative. Q1 sets up the investment base, but the operational and financial proof will depend on how quickly new hubs scale, how stable clinical outcomes remain during expansion, and whether reported margins converge toward the adjusted profile as pre-operational and marketing expenses normalize.

In summary, Gaudium’s Q1 FY27 disclosures show a business in expansion mode. Revenue grew steadily, while profitability softened sharply due to front-loaded spending. Management is betting that standardized processes, the Signature Lab model, and AI-assisted embryology can help it scale without diluting outcomes. Investors will likely track hub ramp-up, margin recovery, and execution on both the IVF expansion and the Lucknow women hospital timeline.